Business Description
Shanghai Henlius Biotech Inc
ISIN : CNE100003N76
Share Class Description:
FRA:2E8: Class HTotal Employee Number:
3,762Compare
Compare
Traded in other countries / regions
02696.Hong Kong2E8.Germany IPO Date
2025-11-05Description
Shanghai Henlius Biotech Inc is a biopharmaceutical company in China with the vision to offer affordable and biologics for patients with a focus on oncology and autoimmune diseases. The Group is engaged in biopharmaceutical R&D, biopharmaceutical services, and biopharmaceutical production and sales. It operates in Mainland China, Asia Pacific (excluding Mainland China), North America, South America, Oceania, and Europe. The company products include HLX01 Rituximab, HLX02(trastuzumab), and others.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.22 | |||||
Equity-to-Asset | 0.32 | |||||
Debt-to-Equity | 0.91 | |||||
Debt-to-EBITDA | 2.69 | |||||
Interest Coverage | 9.05 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 2.76 | |||||
Beneish M-Score | -1.78 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 26.8 | |||||
3-Year Book Growth Rate | 33.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 4.05 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 6.98 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 58.09 | |||||
9-Day RSI | 60.16 | |||||
14-Day RSI | 57.44 | |||||
3-1 Month Momentum % | -9.59 | |||||
6-1 Month Momentum % | -12 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.71 | |||||
Quick Ratio | 0.58 | |||||
Cash Ratio | 0.16 | |||||
Days Inventory | 155.81 | |||||
Days Sales Outstanding | 69.96 | |||||
Days Payable | 167.14 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 74.76 | |||||
Operating Margin % | 13.9 | |||||
Net Margin % | 12.4 | |||||
EBITDA Margin % | 20.14 | |||||
FCF Margin % | 1.58 | |||||
OCF Margin % | 19.57 | |||||
ROE % | 24.1 | |||||
ROA % | 7.25 | |||||
ROIC % | 8.07 | |||||
3-Year ROIIC % | 66.37 | |||||
ROC (Joel Greenblatt) % | 34.2 | |||||
ROCE % | 13.95 | |||||
Years of Profitability over Past 10-Year | 3 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 40.54 | |||||
Forward PE Ratio | 30.1 | |||||
PE Ratio without NRI | 40.54 | |||||
Price-to-Owner-Earnings | 64.1 | |||||
PS Ratio | 5.01 | |||||
PB Ratio | 8.36 | |||||
Price-to-Free-Cash-Flow | 315.96 | |||||
Price-to-Operating-Cash-Flow | 25.62 | |||||
EV-to-EBIT | 39.79 | |||||
EV-to-Forward-EBIT | 34.77 | |||||
EV-to-EBITDA | 27.08 | |||||
EV-to-Forward-EBITDA | 22.74 | |||||
EV-to-Revenue | 5.45 | |||||
EV-to-Forward-Revenue | 4.12 | |||||
EV-to-FCF | 347.03 | |||||
Price-to-GF-Value | 2.16 | |||||
Earnings Yield (Greenblatt) % | 2.51 | |||||
FCF Yield % | 0.31 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Shanghai Henlius Biotech Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 806.912 | ||
| EPS (TTM) (€) | 0.183 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 57.44 | ||
| 14-Day ATR (€) | 0.233535 | ||
| 20-Day SMA (€) | 6.6425 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 5.7 - 9.05 | ||
| Shares Outstanding (Mil) | 545.2 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Shanghai Henlius Biotech Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Shanghai Henlius Biotech Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Shanghai Henlius Biotech Inc Frequently Asked Questions
What is Shanghai Henlius Biotech Inc(FRA:2E8)'s stock price today?
The current price of FRA:2E8 is €7.30. The 52 week high of FRA:2E8 is €9.05 and 52 week low is €5.70.
When is next earnings date of Shanghai Henlius Biotech Inc(FRA:2E8)?
The next earnings date of Shanghai Henlius Biotech Inc(FRA:2E8) is .
Does Shanghai Henlius Biotech Inc(FRA:2E8) pay dividends? If so, how much?
Shanghai Henlius Biotech Inc(FRA:2E8) does not pay dividend.
Press Release
Articles on Shanghai Henlius Biotech Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers